• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Invention of Enmetazobactam: An Indian Triumph in Antimicrobial Drug Discovery.

作者信息

Paul-Satyaseela Maneesh

机构信息

Microvioma, Bengaluru 560109, India.

出版信息

ACS Infect Dis. 2025 Jan 10;11(1):1-3. doi: 10.1021/acsinfecdis.4c00982. Epub 2024 Dec 19.

DOI:10.1021/acsinfecdis.4c00982
PMID:39701946
Abstract

The discovery of antimicrobials was an inflection point in human existence since it contributed enormously to the extension of the human lifespan. Among others, the invention of Enmetazobactam marks a significant milestone in the field of antimicrobial development, especially for India. It is a novel beta-lactamase inhibitor invented by scientists at Orchid Pharma in Chennai, India, and has garnered international attention for its potential to address antimicrobial resistance. It became the first new chemical entity invented in India, clinically developed by Allecra Therapeutics GmbH, to be approved by the U.S. Food & Drug Administration, with additional approvals from the European Medical Agency, the U.K.'s Medicine & Healthcare Products Regulatory Agency, and the Drug Controller General of India.

摘要

相似文献

1
Invention of Enmetazobactam: An Indian Triumph in Antimicrobial Drug Discovery.
ACS Infect Dis. 2025 Jan 10;11(1):1-3. doi: 10.1021/acsinfecdis.4c00982. Epub 2024 Dec 19.
2
Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales.头孢吡肟-恩美他唑巴坦:首个获批用于多重耐药肠杆菌科细菌的头孢吡肟-β-内酰胺酶抑制剂复方制剂。
Future Microbiol. 2025 Mar;20(4):277-286. doi: 10.1080/17460913.2025.2468112. Epub 2025 Feb 26.
3
Cefepime/Enmetazobactam: First Approval.头孢吡肟/恩他唑巴坦:首次批准。
Drugs. 2024 Jun;84(6):737-744. doi: 10.1007/s40265-024-02035-2. Epub 2024 May 18.
4
Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.头孢吡肟与新型β-内酰胺酶抑制剂恩他唑巴坦合剂的肉汤微量稀释 MIC 和纸片扩散药敏试验质控范围的制定。
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00607-19. Print 2019 Aug.
5
Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor.头孢吡肟-恩美他唑巴坦:一种新型β-内酰胺/β-内酰胺酶抑制剂的药物综述。
Ann Pharmacother. 2025 Jun;59(6):570-576. doi: 10.1177/10600280241279904. Epub 2024 Sep 27.
6
Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors.基于结构的 D-巯甲丙脯酸优化用于发现有效的 NDM-1 抑制剂。
Bioorg Med Chem. 2021 Jan 1;29:115902. doi: 10.1016/j.bmc.2020.115902. Epub 2020 Dec 3.
7
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation.头孢吡肟/恩美他唑巴坦:微生物学、药代动力学、药效学及临床评价
Expert Opin Drug Metab Toxicol. 2025 Jan-Feb;21(2):115-123. doi: 10.1080/17425255.2024.2427310. Epub 2024 Nov 10.
8
Penicillanic Acid Sulfones Inactivate the Extended-Spectrum β-Lactamase CTX-M-15 through Formation of a Serine-Lysine Cross-Link: an Alternative Mechanism of β-Lactamase Inhibition.青霉素酸砜通过形成丝氨酸-赖氨酸交联来使超广谱β-内酰胺酶 CTX-M-15 失活:β-内酰胺酶抑制的另一种机制。
mBio. 2022 Jun 28;13(3):e0179321. doi: 10.1128/mbio.01793-21. Epub 2022 May 25.
9
The Development of New Small-Molecule Inhibitors Targeting Bacterial Metallo-β-lactamases.新型靶向细菌金属β-内酰胺酶的小分子抑制剂的研发。
Curr Top Med Chem. 2018;18(10):834-843. doi: 10.2174/1568026618666180518101028.
10
Antimicrobial activities and beta-lactamase inhibitory property of actinomycetes from Atlas forest soils in Northeastern Algeria.阿尔及利亚东北部阿特拉斯森林土壤中放线菌的抗菌活性及β-内酰胺酶抑制特性
World J Microbiol Biotechnol. 2025 Apr 15;41(4):137. doi: 10.1007/s11274-025-04348-0.

引用本文的文献

1
Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical Sector.抗击抗菌药物耐药性:关键利益相关者的作用,重点关注制药行业。
Pharmaceut Med. 2025 Jul 11. doi: 10.1007/s40290-025-00572-z.